Skip to main content

Projecting Uncertain Revenue Growth

Many companies rely on continuous innovation to drive revenue growth. In forecasting revenue growth for a DCF it is difficult to accurately project the direction of revenue with much certainty. Taking an average growth rate is the easiest (and laziest) way, while looking at the product pipeline is more tedious, but can give a clearer picture. The pipeline, while reliable for the medium term (first 1-2 years of projection period), leaves the last 2-3 years of growth ambiguous. 

To help make better projections of growth for an innovation dependent company we may look at research and development expenses. R&D is not a capitalized expense meaning the cost of research is expensed in the time that it occurs instead of expensing it when the information gained contributes to revenue generation. In theory, research is actually an asset that generates revenue over time when it is effective. DCF’s use the cash flows from assets to derive the intrinsic value of a company, so what if we used the R&D expenses to directly forecast future revenue?

In a historical period of company ABC could the R&D expense in year ‘n’ be correlated to the growth of revenue between year ‘n+1’ and ‘n+2’? The answer to that question can only be answered on a company specific basis after correlation tests are run on historical periods. In theory there should be a connection between these two measures in most cases. The key will be determining the amount of time that typically passes before R&D expense is seen as impacting revenue. In other words, the time to market of any new product, if it is a small toy company for example. 

Using the pipeline to project years 1-2 and then R&D to project years 3-5 is a new methodology for forecasting that may provide more accurate forecasting than more general methods under the right circumstances. 

Comments

Popular posts from this blog

The Base Case Is Bullish For HealthSouth

HealthSouth Corporation (Ticker: HLS) operates post-acute rehabilitation centers across the country, with locations more focused in the southern U.S. Their business model is quite simple, they provide physical rehabilitation services based either in their facilities or at an individual’s home. As of December 31, 2014 they acquired Encompass, which broadens their care base to both home health and hospice. Home health provides assistance for individuals at home who require aid in their daily lives, while hospice care is for individuals with terminal diagnoses. HealthSouth’s business model is extremely dependent on their employees, and as a result they have limited economies of scale. Margins are also pretty standard, as Medicare only gives a ‘market basket’ price increase and HealthSouth itself gives their employees an equivalent increase in salary. The business model is extremely dependent on the quality of people they have interacting with and treating patients. HealthSouth unde...

Digi International Makes A Convincing Argument For Growth

  Digi International is a small player in in the internet-of-things and connectivity space. With a market cap of just over $300 million they struggle to compete and innovate with the larger, more well funded companies such as HP. While their core business has been stagnant, they have positioned themselves to launch into an underserved and growing market through 3 small acquisitions. Over the past two years and as recently as January 2017, Digi has acquired Bluenica, Freshtemps and Smart Temps. Combined with Digi’s hardware manufacturing and cloud based platforms, their ‘Digi Cold’ suite of products allows restaurants, pharmacies, grocery stores and food services to remotely and automatically monitor the temperature of their cold storage. The current food safety procedure requires the aforementioned industries to physically check the temperature of their fridge or food, record it by hand on a piece of paper and then upload it to a spreadsheet or similar form of data stor...

Setup For A Correction?

Today we are seeing volatility return to the market. As I write, the S&P 500 and Dow are down 2.08% and 2.39% respectively. Over the past week the VIX has risen over 40%, coming off of a period of historically low closes. While today is exciting, the real story will be told when the markets re-open on Monday. The setup today feels like a familiar story in this historic bull-run. An unforeseen political action, in this case the release of the GOP Surveillance memo, followed by a subsequent decline in the markets. Historically, shares have shown to be resilient; recovery from the surprise Brexit vote took less than 2 weeks for the S&P 500.   The term ‘buy the dip’ has come to characterize our current market. Moving towards the close today and during the open on Monday we will see if the sentiment for buying these pullbacks has shifted. Over the past week I have read second hand reports of brokers having difficulty selling volume in the market. In other wo...